No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TSHA240517C2500
- 0.50
- -0.06-10.71%
15min DelayClose May 17 15:59 ET
1.00High0.50Low
0.50Open0.56Pre Close68 Volume578 Open Interest2.50Strike Price4.02KTurnover2991.30%IV13.27%PremiumMay 17, 2024Expiry Date0.59Intrinsic Value100Multiplier0DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.7430Delta0.1720Gamma3.09Leverage Ratio-2.0644Theta0.0000Rho2.30Eff Leverage0.0002Vega
Intraday
- 5D
- 1D
News
Buy Rating Affirmed: Taysha Gene Therapies Poised for Breakthrough on Pediatric Data and FDA Support
Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Athira Pharma (ATHA) and Taysha Gene Therapies (TSHA)
Analysts Are Bullish on These Healthcare Stocks: Taysha Gene Therapies (TSHA), Biogen (BIIB)
Truist Financial Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)
Taysha Gene Therapies (TSHA) Gets a Buy From Cantor Fitzgerald
Earnings Call Summary | Taysha Gene Therapies(TSHA.US) Q1 2024 Earnings Conference
The following is a summary of the Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript:Financial Performance:Taysha Gene Therapies reported Q1 2024 research and development expenses of
Comments
$Taysha Gene Therapies(TSHA.US$ Reuters· 2 mins ago
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (Rmat) Designation Granted by U.S. FDA for Tsha-102 in Rett Syndrome
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (Rmat) Designation Granted by U.S. FDA for Tsha-102 in Rett Syndrome
1
4
$Taysha Gene Therapies(TSHA.US$ Spinal Delivery Of Taysha's Gene Therapy Shows Promise In Rare Childhood Neurodegenerative Disease
Benzinga· 47 mins ago
An investigational gene therapy, dubbed scAAV9/JeT-GAN, for a rare neurodegenerative disease, giant axonal neuropathy (GAN), that begins in early childhood was well tolerated and showed signs of therapeutic benefit in a Phase 1 trial led by the National Institutes of Health (NIH).
The study was suppo...
Benzinga· 47 mins ago
An investigational gene therapy, dubbed scAAV9/JeT-GAN, for a rare neurodegenerative disease, giant axonal neuropathy (GAN), that begins in early childhood was well tolerated and showed signs of therapeutic benefit in a Phase 1 trial led by the National Institutes of Health (NIH).
The study was suppo...
3
Despite Taysha Gene Therapies' share price surge, its high P/S ratio amidst declining future revenues and a growing industry is worrisome. Investors should remain cautious due to the predicted future revenue decline.
Read more
Papanice : 今天飞吗？
TrytosaveabitOP Papanice: Not sure what it’s going to do yet! Got to see if it gets any volume? GL
Papanice TrytosaveabitOP: 你说能就能了， 吸引力法则 哈哈哈
TrytosaveabitOP Papanice: Hehehe!